On January 12, Eli Lilly announced a strategic partnership with Nvidia to establish an AI innovation laboratory in the San Francisco Bay Area. Over a five-year period, the two companies will invest up to $1 billion in construction, staffing and high-performance computing infrastructure powered by Nvidia’s latest AI processors. The facility will co-locate Eli Lilly’s drug discovery scientists and Nvidia’s AI engineers to develop and train bespoke machine-learning models aimed at shortening the typical 10-plus-year drug development cycle and reducing per-compound R&D costs, which today often exceed $1 billion.

Eli Lilly’s investor presentation highlighted that its recent AI initiatives—including last year’s announcement of an industry-leading supercomputer and the TuneLab platform offered freely to smaller biotech firms—have generated over 200 petaflops of processing capacity and provided access to more than 20 million anonymized clinical trial datapoints. Management projects that successful AI integration could improve probability of clinical success by up to 30%. Coupled with the company’s robust weight-management franchise—Q3 revenue grew 54% year-over-year to $17.6 billion and adjusted EPS of $6.21 represented a 480% increase—investors see the AI lab as a catalyst for sustained long-term margin expansion and new pipeline acceleration.